GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SINTX Technologies Inc (NAS:SINT) » Definitions » Gross Profit

SINT (SINTX Technologies) Gross Profit : $0.92 Mil (TTM As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is SINTX Technologies Gross Profit?

SINTX Technologies's gross profit for the three months ended in Dec. 2024 was $0.04 Mil. SINTX Technologies's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was $0.92 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. SINTX Technologies's gross profit for the three months ended in Dec. 2024 was $0.04 Mil. SINTX Technologies's Revenue for the three months ended in Dec. 2024 was $0.19 Mil. Therefore, SINTX Technologies's Gross Margin % for the quarter that ended in Dec. 2024 was 19.79%.

SINTX Technologies had a gross margin of 19.79% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage

During the past 13 years, the highest Gross Margin % of SINTX Technologies was 75.19%. The lowest was 20.03%. And the median was 36.05%.


SINTX Technologies Gross Profit Historical Data

The historical data trend for SINTX Technologies's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SINTX Technologies Gross Profit Chart

SINTX Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.12 0.16 0.34 0.44 0.44

SINTX Technologies Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.09 0.64 0.16 0.04

Competitive Comparison of SINTX Technologies's Gross Profit

For the Medical Devices subindustry, SINTX Technologies's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SINTX Technologies's Gross Profit Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, SINTX Technologies's Gross Profit distribution charts can be found below:

* The bar in red indicates where SINTX Technologies's Gross Profit falls into.


;
;

SINTX Technologies Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

SINTX Technologies's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as

Gross Profit (A: Dec. 2024 )=Revenue - Cost of Goods Sold
=1.246 - 0.811
=0.44

SINTX Technologies's Gross Profit for the quarter that ended in Dec. 2024 is calculated as

Gross Profit (Q: Dec. 2024 )=Revenue - Cost of Goods Sold
=0.192 - 0.154
=0.04

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.92 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

SINTX Technologies's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.04 / 0.192
=19.79 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


SINTX Technologies  (NAS:SINT) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

SINTX Technologies had a gross margin of 19.79% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage


SINTX Technologies Gross Profit Related Terms

Thank you for viewing the detailed overview of SINTX Technologies's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


SINTX Technologies Business Description

Traded in Other Exchanges
Address
1885 West 2100 South, Salt Lake City, UT, USA, 84119
SINTX Technologies Inc is an advanced ceramics company, focused on providing solutions in a variety of biomedical, technical, and antipathogenic applications. It has grown from focusing primarily on the research, development, and commercialization of medical devices manufactured with silicon nitride to becoming an advanced ceramics company engaged in diverse fields, including biomedical, technical, and antipathogenic applications. Its biomedical products are biocompatible, bioactive, antipathogenic, and to have superb bone affinity. Spinal implants made from SINTX silicon nitride have been successfully implanted in humans in the US, Europe, Brazil, and Taiwan.
Executives
David W. Truetzel director C/O AMEDICA CORPORATION, 1885 WEST 2100 STREET, SALT LAKE CITY UT 84119
David Francis O'brien officer: Chief Operating Officer 1885 WEST 2100 SOUTH, SALT LAKE CITY UT 84119
Ty Lombardi officer: VP Finance C/O AMEDICA CORPORATION, 1885 W 2100 SOUTH, SALT LAKE CITY UT 84119
Eric A Stookey director 5677 AIRLINE ROAD, ARLINGTON TN 38002
Gordon Esplin officer: Vice President, Finance C/O AMEDICA CORPORATION, 1885 WEST 2100 SOUTH, SALT LAKE CITY UT 84119
Kevin Ontiveros officer: See Remarks C/O IMARX THERAPEUTICS INC, 1635 EAST 18TH STREET, TUCSON AZ 85719
Arthur Karl Kipke 10 percent owner C/O AMEDICA CORPORATION, 1885 WEST 2100 STREET SOUTH, SALT LAKE CITY UT 84119
Jay M Moyes director, officer: Chief Fnancial Officer
Vytas Rupinskas officer: SVP, Marketing C/O AMEDICA CORPORATION, 1885 WEST 1200 STREET, SALT LAKE CITY UT 84119
Eric K. Olson director, officer: President and CEO C/O AMEDICA CORPORATION, 1885 WEST 2100 STREET SOUTH, SALT LAKE CITY UT 84119
James P. Abraham officer: SVP, Global Sales C/O AMEDICA CORPORATION, 1885 WEST 1200 STREET, SALT LAKE CITY UT 84119
Christopher Whitfield officer: Chief Commercial Officer C/O AMEDICA CORPORATION, 1885 WEST 1200 STREET, SALT LAKE CITY UT 84119
Max Link director 509 MADISON AVE 14TH FL, NEW YORK NY 10022
Kevin L Davis officer: Chief Operating Officer 9149 SOUTH MONROE PLAZA WAY, SUITE B, SANDY UT 84070
Jeffrey S. White director C/O AMEDICA CORPORATION, 1885 WEST 2100 STREET SOUTH, SALT LAKE CITY UT 84119